3[1]Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey[J]. Antimicrob Chemother, 1998, 41(2): 307-310.
4[2]Segatore B, Setacci D, Perilli M, et al. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999, 43(2): 428-431.
5[3]Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different[J]. Diagn Microbiol Infect Dis, 2001, 41(3): 161-163.
6[4]Kirby JT, Mutnick AH, Jones RN, et al. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000)[J]. Diagn Microbiol Infect Dis, 2002, 43(4): 303-309.
7[5]Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST (tracking resistance in the United States today) and TSN (the surveillance network) data for the United States[J]. Int J Antimicrob Agents, 2002, 19(1): 21-31.
8[6]Sheng WH, Chen YC, Wang JT, et al. Emerging fluoro-quinolone-resistance for common clinically important Gram-negative bacteria in Taiwan[J]. Diagn Microbiol Infect Dis, 2002, 43(2): 141-147.
9[7]Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals[J]. Am J Health-System Pharm, 2003, 60(19): 1962-1970.
10[8]Kukeishi A, Diver JM, Beckthold B, et al. Cloning and nucleotide sequence of P. aeruginosa gyr A gene from PA01 and quinolone-resistant clinical isolates[J]. Antimicrob Agents Chemother, 1994, 38(9): 1944-1952.
